Cardiff Oncology Inc banner

Cardiff Oncology Inc
NASDAQ:CRDF

Watchlist Manager
Cardiff Oncology Inc Logo
Cardiff Oncology Inc
NASDAQ:CRDF
Watchlist
Price: 1.71 USD -1.16% Market Closed
Market Cap: $116.9m

During the last 3 months Cardiff Oncology Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 2% over this period (open performance analysis).

The last transaction was made on Jul 30, 2025 by Pace Gary W , who bought 673.8k USD worth of CRDF shares.

Last Transactions:
Pace Gary W
$+673.8k
Levine James E.
$+12k
Levine James E.
$+14.9k
Levine James E.
$+9.8k
Tannenbaum Renee P
$+34.2k
Pace Gary W
$+910.3k
Pace Gary W
$+41.1k
Pace Gary W
$+22.5k
Erlander Mark
$+14.3k
White Lale
$+24.5k
Levine James E.
$+46.7k
Armitage James O
$+20.2k
Pace Gary W
$+256.5k
Tannenbaum Renee P
$+11k
Pace Gary W
$+202.5k
Levine James E.
$+33.1k
Markin Rodney S
$+29.9k
Kelemen Vicki
$+9.9k
Pace Gary W
$+51k
Erlander Mark
$+10k
Jacob Gary S
$+19.8k
Brancaccio John P
$+32.9k
Armitage James O
$+43.3k
Pace Gary W
$+10.6k
Pace Gary W
$+13.9k
Kelemen Vicki
$-657k
Pace Gary W
$+9.7k
Erlander Mark
$+10k
Adams Thomas Phd
$+20k
Armitage James O
$+15k
Jacob Gary S
$+25k
Markin Rodney S
$+30k
View All Transactions

During the last 3 months Cardiff Oncology Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 2% over this period (open performance analysis).

The last transaction was made on Jul 30, 2025 by Pace Gary W , who bought 673.8k USD worth of CRDF shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
1
673.8k USD

Cardiff Oncology Inc
Insider Trading Chart

Cardiff Oncology Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Cardiff Oncology Inc
Last Insider Transactions

Global
Insiders Monitor

Cardiff Oncology Inc
Glance View

Market Cap
116.9m USD
Industry
Biotechnology

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company is headquartered in San Diego, California and currently employs 22 full-time employees. The company went IPO on 2004-07-27. The firm is focused on developing treatment for cancer patients. Its drug candidate onvansertib, is a polo-like kinase 1 (PLK1) adenosine triphosphate (ATP) competitive inhibitor with the combination of chemotherapy and targeted therapeutics. Its clinical trial includes TROV-054, CRDF-001 and TROV-053. TROV-054 is a Phase I b/2 open-label clinical trial of onvansertib in combination with FOLFIRI (folinic acid, fluorouracil, and irinotecan) and Avastin (bevacizumab). TROV-053 is a Phase II open-label clinical trial of onvansertib in combination with Zytiga (abiraterone acetate)/prednisone. CRDF-001 is a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin, and fluorouracil for second line treatment of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).

CRDF Intrinsic Value
0.02 USD
Overvaluation 99%
Intrinsic Value
Price $1.71

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett